ZFIN ID: ZDB-FISH-150901-25445
Fish name: smob641/b641 (AB)
Genotype: smob641/b641 (AB)
Targeting Reagent: none
HUMAN DISEASE MODELED by smob641/b641 (AB)
No data available
GENE EXPRESSION
Gene expression in smob641/b641 (AB)
RNA expression
Expressed Gene Structure Conditions Figures
alcama standard conditions Fig. 4 with image from Vanderlaan et al., 2005
text only from Ungos et al., 2003
arxa standard conditions Fig. 5 with image from Norton et al., 2005
atoh7 standard conditions text only from Stenkamp et al., 2003
bmp4 standard conditions Fig. 6 with image from Wilm et al., 2005
col2a1a standard conditions Fig. 5 with image from Norton et al., 2005
Fig. 2 with image from Varga et al., 2001
crestin standard conditions Fig. 5 with image,  Fig. 7 with image from Honjo et al., 2005
text only from Ungos et al., 2003
ccn2a standard conditions Fig. 5 with image from Norton et al., 2005
dbx1a standard conditions Fig. 3 with image,  Fig. 4 with image from Scholpp et al., 2006
dlx2a standard conditions Fig. 3 with image,  Fig. 4 with image from Scholpp et al., 2006
Fig. 7 with image from Varga et al., 2001
egr2b standard conditions Fig. 4 with image from Vanderlaan et al., 2005
emx2 standard conditions Fig. 3 with image from Scholpp et al., 2006
emx3 standard conditions Fig. 7 with image from Varga et al., 2001
en1a standard conditions Fig. 4 with image from Ochi et al., 2006
Fig. 4 from Kawakami et al., 2005
en2a standard conditions Fig. 4 from Corbit et al., 2005
chemical treatment: pharmaceutical Fig. 4 from Corbit et al., 2005
fgf8a standard conditions text only from Stenkamp et al., 2003
foxa standard conditions Fig. 2 with image from Norton et al., 2005
foxa1 standard conditions Fig. 7 with image from Norton et al., 2005
foxa2 standard conditions Fig. 2 with image from Norton et al., 2005
Fig. 2 with image from Varga et al., 2001
foxb1a standard conditions Fig. 6 with image from Varga et al., 2001
gata3 standard conditions text only from Teraoka et al., 2004
gli1 standard conditions Fig. 4 with image from Vanderlaan et al., 2005
Fig. 7 with image from Karlstrom et al., 2003
chemical treatment: Cyclopamine Fig. 7 with image from Karlstrom et al., 2003
gli2a standard conditions Fig. 8 with image from Vanderlaan et al., 2005
hbbe1.1 standard conditions Fig. 3 from Gering et al., 2005
hhip standard conditions Fig. S1 with image from Ochi et al., 2006
ins standard conditions text only from Zecchin et al., 2004
irx3a standard conditions Fig. 4 with image from Lewis et al., 2005
isl1a standard conditions Fig. 8 with image from Vanderlaan et al., 2005
text only from Nakano et al., 2004
text only from Ungos et al., 2003
Fig. 3 with image from Lewis et al., 2001
Fig. 2 with image,  Fig. 3 with image from Varga et al., 2001
isl2a standard conditions text only from Ungos et al., 2003
Fig. 1 with image from Lewis et al., 2001
kif7 standard conditions text only from Tay et al., 2005
lhx1a standard conditions text only from Ungos et al., 2003
lhx3 standard conditions Fig. 7 with image from Varga et al., 2001
lhx5 standard conditions Fig. 3 with image from Scholpp et al., 2006
myod1 standard conditions Fig. 7 with image from Hamade et al., 2006
Fig. 2 with image from Barresi et al., 2000
chemical treatment: all-trans-retinoic acid Fig. 7 with image from Hamade et al., 2006
neurod1 standard conditions text only from Ungos et al., 2003
neurog1 standard conditions Fig. S1 with image from Scholpp et al., 2006
nkx2.1 standard conditions Fig. 9 with image from Karlstrom et al., 2003
nkx2.2a standard conditions Fig. 7 with image from Norton et al., 2005
Fig. 4 with image from Vanderlaan et al., 2005
text only from Nakano et al., 2004
text only from Tallafuss et al., 2003
Fig. 2 with image,  Fig. 3 with image from Varga et al., 2001
nkx6.1 standard conditions Fig. 6 with image from Cheesman et al., 2004
ntn1a standard conditions Fig. 4 with image from Vanderlaan et al., 2005
ntn1b standard conditions Fig. 7 with image from Norton et al., 2005
olig2 standard conditions Fig. 5 with image from Lewis et al., 2005
olig4 standard conditions Fig. 6 with image from Filippi et al., 2005
pax2a standard conditions text only from Stenkamp et al., 2003
Fig. 7 with image from Varga et al., 2001
pax2b standard conditions text only from Stenkamp et al., 2003
pax6a standard conditions Fig. 7 with image from Varga et al., 2001
pdx1 standard conditions text only from Nakano et al., 2004
pitx3 standard conditions Fig. S2 with image from Dutta et al., 2005
Fig. 5 from Zilinski et al., 2005
prdm1a standard conditions Fig. 3 with image from Wilm et al., 2005
prox1a standard conditions Fig. 4 from Corbit et al., 2005
chemical treatment: pharmaceutical Fig. 4 from Corbit et al., 2005
prss1 standard conditions text only from Zecchin et al., 2004
ptch2 standard conditions Fig. 4 with image from Vanderlaan et al., 2005
Fig. 2 with image,  Fig. 3 with image from Varga et al., 2001
Fig. 1 with image from Barresi et al., 2000
ptf1a standard conditions text only from Zecchin et al., 2004
rho standard conditions text only from Stenkamp et al., 2003
runx1 standard conditions Fig. 3 from Gering et al., 2005
rx1 standard conditions text only from Stenkamp et al., 2003
sema3h standard conditions text only from Stevens et al., 2005
shha standard conditions Fig. 3 with image from Scholpp et al., 2006
text only from Holzschuh et al., 2003
text only from Tallafuss et al., 2003
Fig. 1 with image,  Fig. 2 with image from Barresi et al., 2000
six3a standard conditions text only from Tallafuss et al., 2003
smo standard conditions Fig. 4 with image from Varga et al., 2001
sox4b standard conditions Fig. 4 with image from Mavropoulos et al., 2005
spon2a standard conditions Fig. 5 with image from Norton et al., 2005
spon2b standard conditions Fig. 5 with image from Norton et al., 2005
zic1 standard conditions Fig. 6 with image from Varga et al., 2001
Reporter gene expression No data available
PHENOTYPE
Phenotype in smob641/b641 (AB)
Phenotype Conditions Figures
adenohypophyseal placode transformed to lens, abnormal standard conditions Fig. 7 with image from Varga et al., 2001
anterior commissure physical object quality, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
anterior macula increased size, abnormal standard conditions Fig. 3 with image from Hammond et al., 2003
brain quality, abnormal standard conditions Fig. for (b641) from Phenotype Annotation (1994-2006)
caudal fin curved ventral, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
caudal fin lacks all parts of type primary motor neuron, abnormal standard conditions Fig. 2 with image from Varga et al., 2001
commissural neuron axon guidance process quality, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
cranial cartilage absent, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
digestive tract morphogenesis process quality, normal standard conditions Fig. 4 from Roy et al., 2001
endocrine cell decreased amount, abnormal standard conditions Fig. 1,  Fig. 3 from Roy et al., 2001
eye adjacent to eye, abnormal standard conditions Fig. 6 with image from Varga et al., 2001
eye fused with eye, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
eye lens deformed, abnormal standard conditions Fig. 7 with image from Varga et al., 2001
floor plate quality, abnormal standard conditions Fig. for (b641) from Phenotype Annotation (1994-2006)
floor plate development decreased process quality, abnormal standard conditions Fig. 1 with image from Varga et al., 2001
forebrain quality, abnormal standard conditions Fig. for (b641) from Phenotype Annotation (1994-2006)
forebrain axon guidance process quality, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
forebrain dorsal/ventral pattern formation process quality, abnormal standard conditions Fig. 7 with image from Varga et al., 2001
gut morphology, normal standard conditions Fig. 4 from Roy et al., 2001
inner ear wholly anteriorized, abnormal standard conditions Fig. 3 with image,  text only from Hammond et al., 2003
lateral floor plate absent, abnormal standard conditions Fig. 2 with image from Varga et al., 2001
liver morphology, abnormal standard conditions Fig. 4 from Roy et al., 2001
liver development process quality, abnormal standard conditions Fig. 4 from Roy et al., 2001
mandibular arch skeleton absent, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
muscle pioneer absent, abnormal standard conditions Fig. 2 with image from Barresi et al., 2000
nervous system quality, abnormal standard conditions Fig. for (b641) from Phenotype Annotation (1994-2006)
optic chiasm absent, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
optic stalk physical object quality, abnormal standard conditions Fig. 7 with image,  Fig. 8 with image from Varga et al., 2001
otolith decreased size, abnormal standard conditions Fig. 3 with image from Hammond et al., 2003
pancreas development disrupted, abnormal standard conditions Fig. 1,  Fig. 3 from Roy et al., 2001
pancreas primordium hypoplastic, abnormal standard conditions Fig. 1,  Fig. 3 from Roy et al., 2001
pars superior ear has extra parts of type anterior crista, abnormal standard conditions Fig. 4 with image from Hammond et al., 2003
pectoral fin decreased size, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
pectoral fin hypoplastic, abnormal standard conditions Fig. 4 with image from Varga et al., 2001
positive regulation of DNA-templated transcription disrupted, abnormal standard conditions Fig. 6 with image from Cheesman et al., 2004
posterior macula aplastic, abnormal standard conditions Fig. 3 with image from Hammond et al., 2003
postoptic commissure absent, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
primary motor neuron decreased amount, abnormal standard conditions Fig. 1 with image,  Fig. 3 with image,  Table 1 from Lewis et al., 2001
retina development in camera-type eye process quality, abnormal standard conditions Fig. 7 with image from Varga et al., 2001
retinal ganglion cell axon guidance process quality, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
secondary motor neuron absent, abnormal standard conditions Fig. 2 with image from Varga et al., 2001
slow muscle cell absent, abnormal standard conditions Fig. 2 with image from Barresi et al., 2000
slow muscle cell decreased amount, abnormal standard conditions Fig. 2 with image from Barresi et al., 2000
somite lacks all parts of type horizontal myoseptum, abnormal standard conditions Fig. 1 with image from Varga et al., 2001
somite morphology, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
somite U-shaped, abnormal standard conditions Table 1 from Lewis et al., 2001
Fig. 1 with image from Varga et al., 2001
somite U-shaped, abnormal chemical treatment: pharmaceutical Fig. 1 with image from Barresi et al., 2000
spinal cord anterior region has fewer parts of type primary motor neuron, abnormal standard conditions Fig. 2 with image from Varga et al., 2001
supraoptic commissure physical object quality, abnormal standard conditions Fig. 8 with image from Varga et al., 2001
trunk posterior region lacks all parts of type primary motor neuron, abnormal standard conditions Fig. 2 with image from Varga et al., 2001
whole organism curved ventral, abnormal standard conditions Fig. 1 with image from Varga et al., 2001

CITATIONS  (52)

Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.